90566-22-6

Basic information

• Product Name: N-(2-aminoethyl)-4-methoxybenzenesulfonamide
• CAS NO: 90566-22-6
• Molecular Formula: C₉H₁₄N₂O₃S
• Molecular Weight: 230.2841
• Mol File: 90566-22-6.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 389°C at 760 mmHg
• Flash Point: 189°C
• Density: 1.25g/cm³
• Vapor Pressure: 2.95E-06mmHg at 25°C
• Refractive Index: 1.547
• CAS DataBase Reference: N-(2-aminoethyl)-4-methoxybenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-aminoethyl)-4-methoxybenzenesulfonamide(90566-22-6)
• EPA Substance Registry System: N-(2-aminoethyl)-4-methoxybenzenesulfonamide(90566-22-6)

Safety Data

• Hazardous Substances Data: 90566-22-6(Hazardous Substances Data)

Upstream product

• 107-15-3 ethylenediamine 
• 154853-46-0 2,4-dinitrophenyl 4-methoxybenzenesulfonate 
• 98-68-0 4-methoxy-phenyl-sulphonyl chloride 
• 2576-47-8 2-bromoethylamine hydrobromide 

Relevant articles and documents

Anticancer profile and anti-inflammatory effect of new N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives

A new series of N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives 11a-o were designed and synthesized based on our previous works. The new series was tested for its anticancer and anti-inflammatory effects. The anticancer profile of

N-(2-ethylamine) benzenesulfonamide cordycepin derivative as well as preparation method and application thereof

The invention discloses an N-(2-ethylamine) benzenesulfonamide cordycepin derivative as well as a preparation method and an application thereof in inhibiting tumor cell proliferation, and the N-(2-ethylamine) benzenesulfonamide cordycepin derivative is pr

Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking

B-Raf mutation was identified as a key target in cancer treatment. Based on structural features of dabrafenib (potent FDA approved B-Raf inhibitor), the design of new NH2-based imidazothiazole derivatives was carried out affording new highly potent derivatives of imidazothiazole-based scaffold with amino substitution on the terminal phenyl ring as well as side chain with sulfonamide group and terminal substituted phenyl ring. In vitro enzyme assay was investigated against V600E B-Raf kinase. Compounds 10l, 10n and 10o showed higher inhibitory activities (IC50 = 1.20, 4.31 and 6.21 nM, respectively). In vitro cytotoxicity evaluation was assessed against NCI-60 cell lines. Most of tested derivatives showed cytotoxic activities against melanoma cell line. Compound 10k exhibited most potent activity (IC50 = 2.68 μM). Molecular docking study revealed that the new designed derivatives preserved the same binding mode of dabrafenib with V600E B-Raf active site. It was investigated that the new modification in the synthesized derivatives (substituted with NH2) had a significant inhibitory activity towards V600E B-Raf. This core scaffold is considered a key compound for further structural and molecular optimization.